Navigation Links
New treatment for age-related macular degeneration within sight
Date:11/29/2007

With 8 million people at high risk for advanced age-related macular degeneration, researchers from Harvard and Japan discovered that the experimental drug, endostatin, may be the cure. A research report published in the December 2007 issue of The FASEB Journal, describes how giving endostatin to mice significantly reduced or eliminated abnormal blood vessel growth within the eye, which is ultimately why the disease causes blindness.

Our study provides intriguing findings that may lead to a better treatment of age-related macular degeneration, said Alexander Marneros, the first author of the report, but clinical studies in patients with age-related macular degeneration are still necessary.

In this study, researchers describe testing the effects of endostatin on mice lacking this naturally occurring substance. The mice without endostatin were about three times more likely to develop advanced age-related macular degeneration (AMD) than normal mice. Then the researchers administered endostatin to both sets of mice. In the mice lacking endostatin, the number of abnormal blood vessels that cause AMD were reduced to normal levels. In control mice with normal levels of endostatin, the number of abnormal blood vessels were practically undetectable.

With Baby Boomers reaching advanced ages, new treatments are desperately needed to keep age-related macular degeneration from becoming a national epidemic, said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal. This research provides hope for those at risk for blindness, and it gives everyone another glimpse of how investments in molecular biology will ultimately pay off in terms of new treatments and cures.

AMD is a progressive disease that affects the part of the eye that allows people to see fine details. The disease gradually destroys sharp, central vision, and in advanced stages ultimately leads to total blindness. Abnormal blood vessel growth, also known as angiogenesis, is a hallmark of advanced AMD. These faulty blood vessels leak fluids and blood, causing catastrophic vision loss. As the name implies, risk for age-related macular degeneration increases with age, and 8 million people are considered to be at high risk for the disease. Of these individuals, approximately 1 to 1.3 million will develop advanced AMD within the next five years. Endostatin is an experimental drug, which is currently being tested to stop cancer in people by restricting the formation of abnormal blood vessels supply blood to tumors. Endostatin is a protein in collagen, and while collagen is used in a range of products for skin care to gelatin desserts, consumption or use of these products does not have any effect on tumors or AMD.

Weissmann added, This research proves once and for all that endostatin functions as the bodys own natural inhibitor of new blood vessel growth as Judah Folkman of Harvard predicted.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... Feb. 28, 2017  ITL Limited ( ASX:ITD ... and strategic partner that provides innovative products and ... management, formally announces its rebrand to ITL Health ... is part of the Company,s unified global rebranding ... an integrated corporate website, ITLHealthGroup.com . ITL,s ...
(Date:2/27/2017)... (PRWEB) , ... February 27, ... ... award-winning high-pressure pasteurized cold-pressed fruit and vegetable drink brand is now available ... Michigan-based Vegesentials USA, LLC to manufacture and distribute the Vegesentials line of ...
(Date:2/27/2017)... and HAMILTON, Bermuda , ... (NASDAQ: ADXS ) and SELLAS ... focused on developing cancer immunotherapies, today announced that ... a novel cancer immunotherapy agent using Advaxis, proprietary ... patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/25/2017)... Garden City, New York (PRWEB) , ... February ... ... announced their partnership with Verified Clinical Trials in an ongoing effort ... the areas of treatment, advocacy, and pharmaceutical research with emphasis on consumers and ...
Breaking Biology Technology: